Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials

Resource type: Publication Publication
  • Authors
    Conforti F.; Pala L.; Pagan E.; Corti C.; Bagnardi V.; Queirolo P.; Catania C.; De Pas T.; Giaccone G.
  • Type
    Original Research
  • Journal
    ESMO
  • Publication Date
    2021
  • Abstract

    In our previous works, we demonstrated that patients’ sex affects the efficacy of immune checkpoint inhibitors (ICIs) in patients with several advanced solid tumors. Here, we assessed the sex-based heterogeneity of efficacy of anti-programmed cell death protein 1 (anti-PD-1)/anti-programmed death-ligand 1 (anti-PD-L1) given as monotherapy, for advanced non-small-cell lung cancer (NSCLC) expressing high PD-L1 levels, to evaluate if available evidence supports this therapeutic option for both women and men.

Access Publication